Patients Rally for Access to ALS Treatment NurOwn Amid FDA Petition Efforts
SHERIDAN, WYOMING – September 23, 2025 –
In a heartfelt campaign fueled by hope and survival, participants in trials of BrainStorm Cell Therapeutics’ NurOwn have submitted a Citizens’ Petition to the FDA, seeking a renewed evaluation of the stem cell therapy rejected in 2022. Their plea centers on real-world results showing a remarkable 90% survival rate in an expanded access program (EAP) — a figure that many say “defies logic” and demands a second look.Patients and Families Demand Action
The drive for reconsideration draws strength from powerful personal stories. Neurologist Danielle Geraldi-Samara appealed to the FDA on Access Newswire, urging approval of NurOwn with a commitment to post-marketing studies. Her plea followed the July 3 Citizens’ Petition, echoing patients' voices determined to change their fate.